Pharmaceutical compositions for treating anxiety

ABSTRACT

Pharmaceutical compositions or functional foods for treating anxiety comprising ginseng saponin (Rg1+Rb1), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating diazepam in the art, the present invention has significant anxielytic efficacy.

FIELD OF THE INVENTION

The present invention relates to a pharmaceutical composition or ahealthcare food manufactured from the raw materials includingginsenoside Rg1 and Rb1, glycyrrhizic acid and jujuba cyclic adenosinemonophosphate (jujuba cAMP) for treating anxiety disorder. Inparticular, the present invention relates to the pharmaceuticalcomposition or the healthcare food for treating anxiety disorder; it hasdefinite functions and components, obvious curative effect, fewer sideeffects and high safety for long-term usage.

BACKGROUND OF THE INVENTION

Psychological disorders are caused by brain dysfunction and afflictedindividuals show abnormalities in awareness, thought, emotion, behavior,will and intelligence, etc. Psychological disorders occupy four in tendiseases, causing the most serious load in society. People are nowpaying more and more attention to psychological dysfunction in thecourse of social development. The medical community and the society as awhole are urgently seeking psychological medicine to combatpsychological disorders. Anxiety disorder is one common psychologicaldysfunction, with anti-anxiety pharmaceuticals being the main method oftreatment.

Anxiety disorder is a psychological disease manifest mainly as anxiousemotion. The main characteristics are breakout or continuous anxiousemotions such as anxiety, catatonia and fear, etc., in combination withsyndromes such as autonomic nerves disturbance, muscle rigidity andexercise disturbance, etc. Since Sigmund Freud had separated anxietydisorder from neurasthenia, scholars around the world have begunlarge-scale studies on anxiety disorder and have accumulated a largeamount of data. According to modern medical research, the etiology ofanxiety disorder includes defects in psychological anatomy,neurotransmitter/modulator-receptor and neuro-endocrine system, etc.

The current mainstream anti-anxiety medicine is benzodiazepine themechanism of which is to modulate the activity of the inhibitoryneurotransmitter, gamma-aminobutyric acid (GABA), to reduce and relievethe symptoms. However, benzodiazepine has many side effects includinginsomnolence, allergy, muscle pain, weakness, nausea, exercisedysfunction, blurred vision, weariness, disturbance and delusion, etc.

In light of the current situation, the search for a new generation ofpharmaceuticals with fewer side effects and more pronounced/potentanti-anxiety qualities has become the center of attention of the entirepharmaceutical world.

It is therefore attempted by the applicant to deal with the abovesituation encountered in the prior art.

SUMMARY OF THE INVENTION

The purpose of the present invention is to provide a pharmaceuticalcomposition or a healthcare food to overcome the insufficiency of thecurrently available treatments for anxiety disorder. The pharmaceuticalcomposition or a healthcare food is manufactured from the raw materialsincluding ginsenoside Rg1 and Rb1, glycyrrhizic acid and jujuba cAMP fortreating anxiety disorder. In particular, the new technical schemeoffering definite functions and components, obvious curative effect,fewer side effects and high safety for long-term usage is provided.

The technical scheme of the present medicine is the result endeavored bythe inventor. The scheme, employing three raw materials includingginseng, liquorice and jujuba, is developed based on the pathologicaland pharmacological theories of modern medicine for treating anxiety;specifically, it integrates past pharmaceutical-targeted research withthe recent knowledge developed in post-receptor mechanism. Ginsenosidefrom ginseng has adenylate cyclase (AC) activity to stimulate cAMPsynthesis and cAMP phosphodiesterase (CAPD) inhibitory activity toreduce cAMP breakdown; glycyrrhizic acid (and glycyrrhetinic acid) fromliquorice are strong inhibitors of CAPD. Ginsenoside Rg1 and Rb1 andglycyrrhizic acid when paired and used collectively further increase theconcentration and activity of cAMP and protein kinase A (PKA)respectively in the organism. The increasing concentration and activityof cAMP can catalyze the phosphorylation of GABA α/β subunits andphosphorylation of the β subunit thereof can amplify the inhibitoryfunction of GABA on neurons to achieve significant anti-anxietyfunctions. Finally, jujuba cAMP from jujube, being the extrinsicnon-hydrolyzable cAMP, can participate in the metastasis of cAMP in theorganism, stimulating the enzyme function and effectively increasing theexpression of cAMP and PKA in the organism, to further enhance theanti-anxiety function. Accordingly, the raw materials includingginsenoside Rg1 and Rb1, glycyrrhizic acid and jujuba cAMP are combinedto maximize the effects of anti-anxiety function of the presentinvention. Ginseng, liquorice and jujuba are commonly usedpharmaceutical materials in Chinese medicine and have been used indietary nourishing medicinal meals for several thousand years. In thislong clinical and dietary history, the safety and efficacy of combineduse of ginseng, liquorice and jujuba have been sufficiently proven. Theinventor's research and experimental results have shown that if thesethree pharmaceutical materials are only normally decocted and extractedto obtain the extract, the extract does not have significantanti-anxiety effect compared with the mainstream anti-anxiety medicinesof the present technology. However, upon further purification of theextract of these three pharmaceutical materials to increase theconcentration of the effective components containing ginsenoside Rg1 andRb1, glycyrrhizic acid and jujuba cAMP, etc., as described in thisinvention, a pharmaceutical composition with significant anti-anxietyfunction is obtained. Animal experimental results clearly demonstratethat the manufactured pharmaceutical composition of the presentinvention has superior anti-anxiety effect compared with thepharmaceutical composition of the mainstream medicine, Diazepam, fortreating anxiety disorder. Furthermore, taking ginseng, liquorice andjujuba would not generate side effects as taking the present mainstreammedicines for treating anxiety. Patients would not cease or refuse thepharmaceutical therapy for worrying about the side effects. The inventorthus submits that ginsenoside Rg1 and Rb1, glycyrrhizic acid and jujubacAMP be the raw materials for manufacturing the pharmaceuticalcomposition or the healthcare food for treating anxiety disorder. Inparticular, the new technical scheme, which has definite functions andcomponents, high safety for long-term usage without side effects,improves the drawbacks generated in the prior art.

Glycyrrhetinic acid has higher liposolubility than glycyrrhizic acid andcan easily enter the brain through the blood-brain barrier. Since theglycyrrhizic acid is converted to glycyrrhetinic acid in the human bodywith almost 100% efficiency, the inhibition of CAPD by glycyrrhizic acidis proceeded by transforming glycyrrhizic acid to glycyrrhetinic acid inthe body. Accordingly, glycyrrhizic acid or glycyrrhetinic acid can bethe raw material for manufacturing the pharmaceutical composition of thepresent invention.

In accordance with one aspect of the present invention, a pharmaceuticalcomposition for treating anxiety disorder is provided. Thepharmaceutical composition includes: ginsenoside having Rg1 and Rb1; aglycyrrhizically related acid being one selected from a group consistingof glycyrrhizic acid, glycyrrhetinic acid and a combination thereof; andjujuba cAMP.

Preferably, the pharmaceutical composition includes 2˜24 parts by weightof ginsenoside, 3˜45 parts by weight of the glycyrrhizically relatedacid and 0.003˜0.4 parts by weight of jujuba cAMP.

Preferably, the pharmaceutical composition includes 4˜11 parts by weightof ginsenoside, 5˜14 parts by weight of the glycyrrhizically relatedacid and 0.01˜0.07 parts by weight of jujuba cAMP.

Preferably, ginsenoside is extracted from ginseng, the glycyrrhizicallyrelated acid is extracted from liquorice, and jujuba cAMP is extractedfrom jujuba.

Preferably, jujuba is extracted for obtaining a first extract having afirst jujuba cAMP concentration, the first extract is further extractedfor obtaining a second extract having a second jujuba concentration, andthe second jujuba cAMP concentration is higher than the first jujubacAMP concentration.

Preferably, the pharmaceutical composition further includes at least oneof a pharmacologically acceptable carrier and an additive.

Preferably, the pharmaceutical composition has a dosage form selectedfrom a group consisting of a tablet, a capsule, a powder, a pill, adust, a solution, a microcapsule, a suspension, an emulsion, a particle,a dropping pill and a roll.

Preferably, the pharmaceutical composition is manufactured as one of ahealthcare food and a supplement.

In accordance with another aspect of the present invention, apharmaceutical composition for treating anxiety disorder is provided.The pharmaceutical composition includes: ginsenoside having Rg1 and Rb1;and a glycyrrhizically related acid being one selected from a groupconsisting of glycyrrhizic acid, glycyrrhetinic acid and a combinationthereof.

Preferably, the pharmaceutical composition includes 2˜24 parts by weightof ginsenoside Rg1 and Rb1, and 3˜45 parts by weight of theglycyrrhizically related acid.

Preferably, the pharmaceutical composition includes 4˜11 parts by weightof ginsenoside Rg1 and Rb1, and 5˜14 parts by weight of theglycyrrhizically related acid.

In accordance with another aspect of the present invention, apharmaceutical composition for treating anxiety disorder is provided.The pharmaceutical composition includes ginseng, liquorice and jujuba.

Preferably, the pharmaceutical composition includes 4˜58 parts by weightof ginseng, 2˜28 parts by weight of liquorice and 2˜38 parts by weightof jujuba.

Preferably, the pharmaceutical composition includes 10˜26 parts byweight of ginseng, 5˜13 parts by weight of liquorice and 4˜16 parts byweight of jujuba.

In accordance with another aspect of the present invention, apharmaceutical composition for treating anxiety disorder is provided.The pharmaceutical composition includes ginseng and liquorice.

Preferably, the pharmaceutical composition includes 4˜58 parts by weightof ginseng and 2˜28 parts by weight of liquorice.

Preferably, the pharmaceutical composition includes 10˜26 parts byweight of ginseng and 5˜13 parts by weight of liquorice.

In accordance with another aspect of the present invention, apreparation method of jujuba cAMP of a pharmaceutical composition fortreating anxiety disorder is provided. The preparation method includessteps of: (a) extracting jujuba for obtaining a first extract having afirst jujuba cAMP concentration; and (b) purifying the first extract forobtaining a second extract having a second jujuba cAMP concentration.The second jujuba cAMP concentration is higher than the first jujubacAMP concentration.

Preferably, step (b) is processed by chromatographing the first extractwith a macroporous resin bound with an aldehyde group.

Preferably, step (b) further includes steps of: (b1) chromatographingthe first extract with an OU-2 macroporous resin bound with an aldehydegroup; and (b2) chromatographing the first extract with an ME-2macroporous resin bound with the aldehyde group.

The pharmaceutical composition described in the specification and theclaims of the present invention for treating anxiety disorder is thecore content of the present invention. After the present invention ispublished, one skilled in the art can proceed the normalincrease/decrease or substitute for other effective components of theherbal medicine (such as onjisaponin, saikosaponin and liquoricecoumarin, etc.) having identical effects/functions to theabove-mentioned medicine in accordance with the theory of Chinesemedicine or related theory of modern pharmacology. The substitutions ofthis normal increase/decrease, the herbal medicine having similarmechanism, other identical CAPD inhibitor, AC activator, orcorresponding effective components belong to the normal technicalactivities for one skilled in the art. Therefore, the substitutions arein the protecting scope of the present invention.

The above objectives and advantages of the present invention will becomemore readily apparent to those ordinarily skilled in the art afterreviewing the following detailed descriptions and accompanying drawings,in which:

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a flowchart showing a preparation method of a pharmaceuticalcomposition in accordance with a first preferred embodiment of thepresent invention;

FIG. 2 is a flowchart showing a preparation method of a pharmaceuticalcomposition in accordance with a second preferred embodiment of thepresent invention;

FIG. 3 is a flowchart showing a preparation method of a pharmaceuticalcomposition in accordance with a third preferred embodiment of thepresent invention;

FIG. 4 is a flowchart showing a preparation method of a pharmaceuticalcomposition in accordance with a fourth preferred embodiment of thepresent invention;

FIG. 5 is a flowchart showing a preparation method of a pharmaceuticalcomposition in accordance with a fifth preferred embodiment of thepresent invention; and

FIG. 6 is a flowchart showing a preparation method of a pharmaceuticalcomposition in accordance with a sixth preferred embodiment of thepresent invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention will now be described more specifically withreference to the following Embodiments. It is to be noted that thefollowing descriptions of preferred Embodiments of this invention arepresented herein for purpose of illustration and description only; it isnot intended to be exhaustive or to be limited to the precise formdisclosed.

In order to accomplish the purpose of the present invention, thetechnical schemes of the present invention are particularly provided asfollows.

Example 1

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials of ginseng andliquorice.

Example 2

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials having 4˜58parts by weight of ginseng and 2˜28 parts by weight of liquorice.

Example 3

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials having 10˜26parts by weight of ginseng and 5˜13 parts by weight of liquorice.

Example 4

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials of ginseng,liquorice and jujuba.

Example 5

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials having 4˜58parts by weight of ginseng, 2˜28 parts by weight of liquorice and 2˜38parts by weight of jujuba.

Example 6

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials having 10˜26parts by weight of ginseng, 5˜13 parts by weight of liquorice and 4˜16parts by weight of jujuba.

Example 7

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials of ginsenosideRg1 and Rb1, and glycyrrhizic acid (or glycyrrhetinic acid).

Example 8

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from 2˜24 parts by weight ofginsenoside Rg1 and Rb1, and 3˜45 parts by weight of glycyrrhizic acid(or glycyrrhetinic acid).

Example 9

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from 4˜11 parts by weight ofginsenoside Rg1 and Rb1, and 5˜14 parts by weight of glycyrrhizic acid(or glycyrrhetinic acid).

Example 10

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials of the ginsengextract having the above-mentioned parts by weight of ginsenoside Rg1and Rb1, and the liquorice extract having the above-mentioned parts byweight of glycyrrhizic acid.

Example 11

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials of ginsenosideRg1 and Rb1, glycyrrhizic acid (or glycyrrhetinic acid) and jujuba cAMP.

Example 12

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials having 2˜24parts by weight of ginsenoside Rg1 and Rb1, 3˜45 parts by weight ofglycyrrhizic acid (or glycyrrhetinic acid) and 0.003˜0.4 parts by weightof jujuba cAMP.

Example 13

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials having 4˜11parts by weight of ginsenoside Rg1 and Rb1, 5˜14 parts by weight ofglycyrrhizic acid (or glycyrrhetinic acid) and 0.01˜0.07 parts by weightof jujuba cAMP.

Example 14

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials of the ginsengextract having the above-mentioned parts by weight of ginsenoside Rg1and Rb1, the liquorice extract having the above-mentioned parts byweight of glycyrrhizic acid, and the jujuba extract having theabove-mentioned parts by weight of jujuba cAMP.

Example 15

The pharmaceutical composition of the present invention is provided,wherein the raw material having jujuba cAMP is the second extractdescribed as follows. First, jujuba is extracted for obtaining the firstextract, then the first extract is further extracted for obtaining thesecond extract, wherein the jujuba cAMP concentration of the secondextract is higher than that of the first extract.

Example 16

The preparation method of the pharmaceutical composition including theraw material of jujuba cAMP is provided. The preparation method thereofincludes the steps as follows.

(a) Jujuba is extracted for obtaining a first extract; and

(b) the first extract is further purified for obtaining a secondextract, and the jujuba cAMP concentration of the second extract ishigher than that of the first extract.

Example 17

In the aforementioned preparation method, the step (b) is processed bychromatographing, absorbing and separating jujuba cAMP of the firstextract with the macroporous resin bound with the aldehyde group.

Example 18

In the aforementioned preparation method, the step (b) is processed bychromatographing, absorbing and separating jujuba cAMP of the firstextract with the OU-2 macroporous resin bound with the aldehyde group.

Example 19

In the aforementioned preparation method, the step (b) is processed bychromatographing, absorbing and separating jujuba cAMP of the firstextract with the ME-2 macroporous resin bound with the aldehyde group.

Example 20

The pharmaceutical composition of the present invention includes thepharmacologically acceptable carriers or additives.

Example 21

The pharmaceutical composition of the present invention can bemanufactured as a dosage form, and the dosage forms is selected from anyone of a tablet, a capsule, a powder, a pill, a dust, a solution, amicrocapsule, a suspension, an emulsion, a particle, a dropping pill, aroll and the pharmacologically oral pharmaceutical dosage form.

Example 22

The pharmaceutical composition of the present invention further can bemanufactured as healthcare food and nutrient supplements.

In order to accomplish the purpose of the present invention, thepreparation methods of the pharmaceutical composition are provided asfollows.

Method 1:

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the extract having ginsenoside Rg1and Rb1 and glycyrrhizic acid, wherein the extract is extracted andpurified from the raw materials having 4˜58 parts by weight of ginsengand 2˜28 parts by weight of liquorice.

Method 2:

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the extract having ginsenoside Rg1and Rb1 and glycyrrhizic acid, wherein the extract is extracted andpurified from the raw materials having 10˜26 parts by weight of ginsengand 5˜13 parts by weight of liquorice.

Method 3:

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the extract having ginsenoside Rg1and Rb1, glycyrrhizic acid and jujuba cAMP, wherein the extract isextracted and purified from the raw materials having 4˜58 parts byweight of ginseng, 2˜28 parts by weight of liquorice and 2˜38 parts byweight of jujuba.

Method 4:

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the extract having ginsenoside Rg1and Rb1, glycyrrhizic acid and jujuba cAMP, wherein the extract isextracted and purified from the raw materials having 10˜26 parts byweight of ginseng, 5˜13 parts by weight of liquorice and 4˜16 parts byweight of jujuba.

Method 5:

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from (1) the extracts havingginsenoside Rg1 and Rb1 extracted and purified from ginseng, andglycyrrhizic acid extracted and purified from liquorice; or (2) theprepared raw materials having ginsenoside Rg1 and Rb1, and glycyrrhizicacid (or glycyrrhetinic acid).

Method 6:

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials having 2˜24parts by weight of ginsenoside Rg1 an Rb1, and 3˜45 parts by weight ofglycyrrhizic acid (or glycyrrhetinic acid).

Method 7:

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials having 4˜11parts by weight of ginsenoside Rg1 an Rb1, and 5˜14 parts by weight ofglycyrrhizic acid (or glycyrrhetinic acid).

Method 8:

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from (1) the extracts havingginsenoside Rg1 and Rb1, glycyrrhizic acid and jujuba cAMP respectivelyextracted and purified from ginseng, liquorice and jujuba; or (2) theprepared raw materials having ginsenoside Rg1 and Rb1, glycyrrhizic acid(or glycyrrhetinic acid) and jujuba cAMP.

Method 9:

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials having 2˜24parts by weight of ginsenoside Rg1 an Rb1, 3˜45 parts by weight ofglycyrrhizic acid (or glycyrrhetinic acid) and 0.003˜0.4 parts by weightof jujuba cAMP.

Method 10:

The pharmaceutical composition of the present invention for treatinganxiety disorder is manufactured from the raw materials having 4˜11parts by weight of ginsenoside Rg1 an Rb1, 5˜14 parts by weight ofglycyrrhizic acid (or glycyrrhetinic acid) and 0.01˜0.07 parts by weightof jujuba cAMP.

Method 11:

The preparation method of the pharmaceutical composition including theraw material of jujuba cAMP is provided. The preparation method thereofincludes the steps as follows.

(a) Jujuba is extracted for obtaining a first extract; and

(b) the first extract is further purified for obtaining a secondextract, and the jujuba cAMP concentration of the second extract ishigher than that of the first extract.

Method 12:

In the aforementioned preparation method, the step (b) is processed bychromatographing, absorbing and separating jujuba cAMP of the firstextract with the macroporous resin bound with the aldehyde group.

Method 13:

In the aforementioned preparation method, the step (b) is processed bychromatographing, absorbing and separating jujuba cAMP of the firstextract with the OU-2 macroporous resin bound with the aldehyde group.

Method 14:

In the aforementioned preparation method, the step (b) is processed bychromatographing, absorbing and separating jujuba cAMP of the firstextract with the ME-2 macroporous resin bound with the aldehyde group.

Method 15:

The pharmaceutical composition of the present invention includes thepharmacologically acceptable carriers or additives.

Method 16:

The pharmaceutical composition of the present invention can bemanufactured as a dosage form, and the dosage forms is selected from anyone of a tablet, a capsule, a powder, a pill, a dust, a solution, amicrocapsule, a suspension, an emulsion, a particle, a dropping pill, aroll and the pharmacologically oral pharmaceutical dosage form.

Method 17:

The raw materials described in the present invention can be manufacturedas the medicines, healthcare food and nutrient supplements for treatinganxiety disorder in accordance with the Good Manufacturing Practice(GMP) pharmaceutical standards and the method of healthcare foodproducing/manufacturing standards.

THE PREFERRED EMBODIMENT

The present invention is further illustrated as follows by combining thefigures and the preferred embodiments.

Embodiment 1

Please refer to FIG. 1, which is the flowchart showing a preparationmethod of a pharmaceutical composition in accordance with a firstpreferred embodiment of the present invention. In FIG. 1, after 20 kg ofginseng (101) is fractured, the fractured ginseng is heated to extractby 70% of the ethanol solution. The extracted ginseng is separated andpurified by chromatography, and dried, and 0.8 kg of the ginseng extracthaving 120 g of ginsenoside Rg1 and Rb1 is obtained (102). Further,after 10 kg of liquorice (103) is fractured, the fractured liquorice issoaked at room temperature for 12 hours. The soaked liquorice isextracted by decoction and alcohol sedimentation, concentrated anddried, and 2 kg of the liquorice extract having 200 g of glycyrrhizicacid is obtained (104). Next, 150 g of the obtained ginseng extract and200 g of the obtained liquorice extract are pulverized and mixed, and350 g of the pharmaceutical composition (containing 22.5 g ofginsenoside Rg1 and Rb1, and 20 g of glycyrrhizic acid) of the presentinvention is obtained (105).

Embodiment 2

Please refer to FIG. 2, which is the flowchart showing a preparationmethod of a pharmaceutical composition in accordance with a secondpreferred embodiment of the present invention. In FIG. 2, after theprepared 3.96 g of glycyrrhetinic acid having 96% purity (202) and 200 gof the ginseng extract obtained in Embodiment 1 (201) are pulverized andmixed, 203.96 g of the pharmaceutical composition (containing 30 g ofginsenoside Rg1 and Rb1, and 3.8 g of glycyrrhetinic acid) of thepresent invention is obtained (203).

Embodiment 3

Please refer to FIG. 3, which is the flowchart showing a preparationmethod of a pharmaceutical composition in accordance with a thirdpreferred embodiment of the present invention. In FIG. 3, after 3.4 g ofthe prepared ginsenoside Rg1 having 90% purity (301), 7.8 g of theprepared ginsenoside Rb1 having 90% purity (302) and 36.8 g ofglycyrrhizic acid having 90% purity (303) are pulverized and mixed, 48 gof the pharmaceutical composition (containing 10 g of ginsenoside Rg1and Rb1, and 35 g of glycyrrhizic acid) of the present invention isobtained (304).

Embodiment 4

Please refer to FIG. 4, which is the flowchart showing a preparationmethod of a pharmaceutical composition in accordance with a fourthpreferred embodiment of the present invention. In FIG. 4, 10 kg ofjujuba (401) is fractured and soaked in the water at room temperature,then the soaked jujuba is extracted by decoction and alcoholsedimentation for obtaining the jujuba extract, which is furtherabsorbed and separated by the OU-2 and ME-2 macroporous resinssequentially, and dried. Thirty (30) g of the jujuba extract containing0.3 g of jujuba cAMP is obtained to be the raw material for preparingthe medicine of the present invention (402).

Afterwards, after 150 g of the ginseng extract and 200 g of theliquorice extract obtained in Embodiment 1 are pulverized and mixed with3 g of the above-mentioned jujuba extract, and 353 g of thepharmaceutical composition (containing 22.5 g of ginsenoside Rg1 andRb1, 20 g of glycyrrhizic acid and 0.03 g of jujuba cAMP) of the presentinvention is obtained (403).

Embodiment 5

Please refer to FIG. 5, which is the flowchart showing a preparationmethod of a pharmaceutical composition in accordance with a fifthpreferred embodiment of the present invention. In FIG. 5, after 150 g ofthe ginseng extract (501) and 200 g of the liquorice extract (502)obtained in Embodiment 1 respectively are pulverized and mixed with 0.5g of the jujuba extract obtained in Embodiment 4 (503), 350.5 g of thepharmaceutical composition (containing 22.5 g of ginsenoside Rg1 andRb1, 20 g of glycyrrhizic acid and 0.005 g of jujuba cAMP) of thepresent invention is obtained (504).

Embodiment 6

Please refer to FIG. 6, which is the flowchart showing a preparationmethod of a pharmaceutical composition in accordance with a sixthpreferred embodiment of the present invention. In FIG. 6, after 6.8 g ofthe prepared ginsenoside Rg1 having 90% purity (601), 15.6 g of theprepared ginsenoside Rb1 having 90% purity (602), 26 g of glycyrrhetinicacid having 96% purity (603) and 10 g of the jujuba extract obtained inEmbodiment 4 (604) are pulverized and mixed, 58.4 g of thepharmaceutical composition (containing 20 g of ginsenoside Rg1 and Rb1,25 g of glycyrrhetinic acid and 0.1 g of jujuba cAMP) of the presentinvention is obtained (605).

Experiment 1 The Influence of Embodiment 1 in the Light-Dark TransitionExperiment of the Mouse

1.1 Experimental animals: Kunming (KM) mice, male, 24˜26 g of bodyweight, secondary, are provided by the Experimental Animal ScienceDepartment of Capital Medical University, Beijing.

1.2 Experimental pharmaceuticals: The pharmaceutical of Embodiment 1 isprovided by Beijing Wonner Biotech. Ltd. Co., and Diazepam is theproduct of Tianjin Jinhuei Amino Acid Co. Ltd.

1.3 Experimental equipment: Self-made light-dark transition box.

1.4 Dose designs: 1. High dose of Embodiment 4 (80 mg/kg/d); 2. middledose of Embodiment 4 (40 mg/kg/d); and 3. low dose of Embodiment 4 (20mg/kg/d).

1.5 Experimental Method and Result:

1.5.1 Group division and administration of drug: The mice are groupedrandomly as 5 groups, and 10 mice are in each group. 1. High dose ofEmbodiment 1 (80 mg/kg); 2. middle dose of Embodiment 1 (40 mg/kg); 3.low dose of Embodiment 1 (20 mg/kg); 4. Diazepam (2.5 mg/kg); and 5.physiological saline (normal saline, NS). The drugs are fed into themouse stomach once every day, and the mouse is administered forcontinuous 7 days. During the period of administration, the mouse eatsand drinks freely, and the experiment is proceeded after 1 hour of thelast administration of drug on the eighth day.

1.5.2 Experimental Method:

Mouse light-dark transition test: The dark chamber occupies one third ofthe light-dark transition chamber (44 cm×21 cm×21 cm), and the top iscapped. The light chamber occupies two third thereof and is illuminatedbrightly. A door between two chambers is disposed for the passage of themouse. The mouse is placed in the center of the light chamber when theexperiment begins, and the mouse's back faces the dark chamber. Thetimes that the mouse enters into the dark chamber and returns to thelight chamber within 10 minutes are determined, and the times thereofare the index for evaluating the anti-anxiety function of the drugs.

1.5.3 Statistic calculation: The experimental data are represented asX±SD, and the experimental result is calculated as one-way analysis ofvariance (one-way ANOVA) by SPSS 11.5 statistic software.

1.5.4 Experimental result: Please refer to Table 1.

TABLE 1 The influence of Embodiment 1 on the times of the mouselight-dark transition experiment Animal Times of passing from dark Groupnumber chamber to light chamber High dose of Embodiment 1 10 11.2 ±3.84*  Middle dose of Embodiment 1 10 13.1 ± 5.38** Low dose ofEmbodiment 1 10 13.5 ± 4.65** Diazepam 10 11.3 ± 4.54*  Normal saline(NS) 10 6.2 ± 4.32  In comparison with the NS group: *P < 0.05, and **P< 0.01.

1.6 Description: The light-dark transition experiment adopted in thepresent experiment is built up on the basis that the mouse congenitallyhates the bright light and the voluntary exploring behavior to the newenvironment. The clinical medicine (Diazepam) for treating anxiety inhuman beings and the Embodiment 1 have excellent correlation onimproving the function of the increasing voluntary exploring behavior onthis mouse model. According to the above experiment, it can be foundthat the high, middle and low doses of Embodiment 1 of the presentinvention and Diazepam all significantly increase the times that themouse passes from the dark chamber to the light chamber, and havestatistical meanings while comparing with the physiological saline. Theexperimental result has proven that the Embodiment 1 has anti-anxietyeffect.

1.7 Conclusion: According to the above experimental result, it showsthat the high, middle and low doses of Embodiment 1 of the presentinvention and Diazepam all significantly increase the times that themouse passes from the dark chamber to the light chamber. The resultshows the Embodiment 1 having anti-anxiety effect.

Experiment 2 The Influence of Embodiment 4 in the Mouse Light-DarkTransition Experiment

2.1 Experimental animals: Kunming (KM) mice, male, 24˜26 g of bodyweight, secondary, are provided by the Experimental Animal ScienceDepartment of Capital Medical University, Beijing.

2.2 Experimental pharmaceuticals: The pharmaceutical of Embodiment 4 isprovided by Beijing Wonner Biotech. Ltd. Co., and Diazepam is theproduct of Tianjin Jinhuei Amino Acid Co. Ltd.

2.3 Experimental equipment: Self-made light-dark transition box.

2.4 Dose designs: 1. High dose of Embodiment 4 (80 mg/kg/d); 2. middledose of Embodiment 4 (40 mg/kg/d); and 3. low dose of Embodiment 4 (20mg/kg/d).

2.5 Experimental Method and Result:

2.5.1 Group division and administration of drug: The mice are groupedrandomly as 5 groups, and 10 mice are in each group. 1. High dose ofEmbodiment 4 (80 mg/kg); 2. middle dose of Embodiment 4 (40 mg/kg); 3.low dose of Embodiment 4 (20 mg/kg); 4. Diazepam (2.5 mg/kg); and 5.physiological saline (normal saline, NS). The drugs are fed into themouse stomach once every day, and the mouse is administered forcontinuous 7 days. During the period of administration, the mouse eatsand drinks freely, and the experiment is proceeded after 1 hour of thelast administration of drug on the eighth day.

2.5.2 Experimental Method:

Mouse light-dark transition test: The dark chamber occupies one third ofthe light-dark transition chamber (44 cm×21 cm×21 cm), and the top iscapped. The light chamber occupies two third thereof and is illuminatedbrightly. A door between two chambers is disposed for the passage of themouse. The mouse is placed in the center of the light chamber when theexperiment begins, and the mouse's back faces the dark chamber. Thetimes that the mouse enters into the dark chamber and returns to thelight chamber within 10 minutes are determined, and the times thereofare the index for evaluating the anti-anxiety function of the drugs.

2.5.3 Statistic calculation: The experimental data are represented asX±SD, and the experimental result is calculated as one-way ANOVA by SPSS11.5 statistic software.

2.5.4 Experimental result: Please refer to Table 2.

TABLE 2 The influence of Embodiment 4 on the times of the mouselight-dark transition experiment Animal Times of passing from dark Groupnumber chamber to light chamber High dose of Embodiment 4 10 11.6 ±2.53*  Middle dose of Embodiment 4 10 13.9 ± 3.76** Low dose ofEmbodiment 4 10 13.4 ± 4.12** Diazepam 10 11.7 ± 4.47*  Normal saline(NS) 10 6.8 ± 3.85  In comparison with the NS group: *P < 0.05, and **P< 0.01.

2.6 Description: The light-dark transition experiment adopted in thepresent experiment is built on the basis that the mouse congenitallyhates the bright light and the voluntary exploring behavior to the newenvironment. The clinical pharmaceutical (Diazepam) for treating anxietyin human beings and the Embodiment 4 have excellent correlation onimproving the function of the increasing voluntary exploring behavior ofthe mouse on this model. According to the above experiment, it can befound that the high, middle and low doses of Embodiment 4 of the presentinvention and Diazepam all significantly increase the times that themouse passes from the dark chamber to the light chamber, and havestatistical meanings while comparing with the normal saline. Theexperimental result has proven that the Embodiment 4 has anti-anxietyeffect.

2.7 Conclusion: According to the above experimental result, the high,middle and low doses of Embodiment 4 of the present invention andDiazepam all significantly increase the times that the mouse passes fromthe dark chamber to the light chamber. The result demonstrates theEmbodiment 4 has anti-anxiety function.

INDUSTRIAL USEFULNESS

The application scope of the pharmaceutical composition of the presentinvention for treating anxiety disorder lies in that:

1. the described pharmaceutical composition of the present invention fortreating anxiety disorder can include the pharmacologically acceptableadditives;

2. the described pharmaceutical composition of the present invention fortreating anxiety disorder can be manufactured as the known dosage forms,such as powder, capsule, tablet, etc.; and

3. the described pharmaceutical composition of the present invention fortreating anxiety disorder can be manufactured as the healthcare food fortreating depression.

While the invention has been described in terms of what is presentlyconsidered to be the most practical and preferred Embodiments, it is tobe understood that the invention needs not be limited to the disclosedEmbodiments. On the contrary, it is intended to cover variousmodifications and similar arrangements included within the spirit andscope of the appended claims, which are to be accorded with the broadestinterpretation so as to encompass all such modifications and similarstructures.

1-31. (canceled)
 32. A pharmaceutical composition for treating ananxiety disorder, comprising: a ginsenoside having an Rg1 and an Rb1; aglycyrrhizically related acid being one selected from a group consistingof a glycyrrhizic acid, a glycyrrhetinic acid and a combination thereof;and a jujuba cyclic adenosine monophosphate (jujuba cAMP).
 33. Thepharmaceutical composition according to claim 32 comprising 2˜24 partsby weight of the ginsenoside, 3˜45 parts by weight of theglycyrrhizically related acid and 0.003 0.4 parts by weight of thejujuba cAMP.
 34. The pharmaceutical composition according to claim 33comprising 4 11 parts by weight of the ginsenoside, 5˜14 parts by weightof the glycyrrhizically related acid and 0.01˜0.07 parts by weight ofthe jujuba cAMP.
 35. The pharmaceutical composition according to claim32, wherein the ginsenoside is extracted from a ginseng, theglycyrrhizically related acid is extracted from a liquorice, and thejujuba cAMP is extracted from a jujuba.
 36. The pharmaceuticalcomposition according to claim 35, wherein the jujuba is extracted forobtaining a first extract having a first jujuba cAMP concentration, thefirst extract is further extracted for obtaining a second extract havinga second jujuba concentration, and the second jujuba cAMP concentrationis higher than the first jujuba cAMP concentration.
 37. Thepharmaceutical composition according to claim 32 further comprising atleast one of a pharmacologically acceptable carrier and an additive. 38.The pharmaceutical composition according to claim 32 having a dosageform selected from a group consisting of a tablet, a capsule, a powder,a pill, a dust, a solution, a microcapsule, a suspension, an emulsion, aparticle, a dropping pill and a roll.
 39. The pharmaceutical compositionaccording to claim 32 being manufactured as one of a healthcare food anda supplement.
 40. A pharmaceutical composition for treating an anxietydisorder, comprising: a ginsenoside having an Rg1 and an Rb1; and aglycyrrhizically related acid being one selected from a group consistingof a glycyrrhizic acid, a glycyrrhetinic acid and a combination thereof.41. The pharmaceutical composition according to claim 40 comprising 2˜24parts by weight of the ginsenoside and 3˜45 parts by weight of theglycyrrhizically related acid.
 42. The pharmaceutical compositionaccording to claim 41 comprising 4˜11 parts by weight of the ginsenosideand 5˜14 parts by weight of the glycyrrhizically related acid.
 43. Apharmaceutical composition for treating an anxiety disorder, comprisinga ginseng, a liquorice and a jujuba.
 44. The pharmaceutical compositionaccording to claim 43 comprising 4˜58 parts by weight of the ginseng,2˜28 parts by weight of the liquorice and 2˜38 parts by weight of thejujuba.
 45. The pharmaceutical composition according to claim 44comprising 10˜26 parts by weight of the ginseng, 5˜13 parts by weight ofthe liquorice and 4˜16 parts by weight of the jujuba.
 46. Apharmaceutical composition for treating an anxiety disorder, comprisinga ginseng and a liquorice.
 47. The pharmaceutical composition accordingto claim 46 comprising 4˜58 parts by weight of the ginseng and 2˜28parts by weight of the liquorice.
 48. The pharmaceutical compositionaccording to claim 47 comprising 10˜26 parts by weight of the ginsengand 5˜13 parts by weight of the liquorice.
 49. A preparation method of ajujuba cyclic adenosine monophosphate (jujuba cAMP) of a pharmaceuticalcomposition for treating an anxiety disorder, comprising steps of: (a)extracting a jujuba for obtaining a first extract having a first jujubacAMP concentration; and (b) purifying the first extract for obtaining asecond extract having a second jujuba cAMP concentration, wherein thesecond jujuba cAMP concentration is higher than the first jujuba cAMPconcentration.
 50. The preparation method according to claim 49, whereinthe step (b) is processed by chromatographing the first extract with amacroporous resin bound with an aldehyde group.
 51. The preparationmethod according to claim 49, wherein the step (b) further comprisessteps of: (b1) chromatographing the first extract with an OU-2macroporous resin bound with an aldehyde group; and (b2)chromatographing the first extract with an ME-2 macroporous resin boundwith the aldehyde group.